Clinical Trials · NCT07817875
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
- Phase
- Phase 3
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 150
- Start date
- Sep 2026
- Locations
- 84 sites, 10 countries
- Primary endpoint
- Percent Change from Baseline in Body Mass Index (BMI)